GOTHENBURG, Sweden, April 16, 2024 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), today announced that the company's annual report and corporate governance report for the financial year 2023 are now available, in Swedish, on the company's website, www.isofolmedical.com.

The information in the press release is intended for investors.

For further information, please contact
Isofol Medical AB (publ)
Petter Segelman Lindqvist, Chief Executive Officer 
E-mail: petter.s.lindqvist@isofolmedical.com
Phone: +46 (0) 739 60 12 56

Magnus Hurst, Chief Financial Officer
E-mail: magnus.hurst@isofolmedical.com
Phone: +46 (0) 738 73 34 18

This information is information that Isofol Medical AB (publ) is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 16:50 CEST on April 16, 2024.

About Isofol Medical AB (publ) 
Isofol Medical AB (publ) aims to raise the quality of life and increase the survival rate for patients with severe forms of cancer. The company’s drug candidate arfolitixorin is being developed with the purpose of increasing the efficacy of standard first-line treatment for several forms of solid tumours, including colorectal cancer. The next step in the clinical development program is currently being prepared based on a new dosage regimen that is expected to optimize arfolitixorin’s efficacy. Isofol Medical AB (publ) is traded on Nasdaq Stockholm.

www.isofolmedical.com

Attachments
Isofol_Annual Report 2023_final (Swedish)
20240416_Isofol_PM_Annual Report 2023_final

© Modular Finance, source Nordic Press Releases